JP2007517895A - 炎症疾患を処置するのに有用な2−(アミノ置換)−4−アリールピリミジンおよび関連化合物 - Google Patents
炎症疾患を処置するのに有用な2−(アミノ置換)−4−アリールピリミジンおよび関連化合物 Download PDFInfo
- Publication number
- JP2007517895A JP2007517895A JP2006549475A JP2006549475A JP2007517895A JP 2007517895 A JP2007517895 A JP 2007517895A JP 2006549475 A JP2006549475 A JP 2006549475A JP 2006549475 A JP2006549475 A JP 2006549475A JP 2007517895 A JP2007517895 A JP 2007517895A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- membered
- phenyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1CNC(CN*C2CC2)C1 Chemical compound CC1CNC(CN*C2CC2)C1 0.000 description 15
- ZHMNTLOSFHIVMF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(Cc1cccc(-c(nc(NCCc(cc2F)ccc2O)nc2)c2F)c1)S(C)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(Cc1cccc(-c(nc(NCCc(cc2F)ccc2O)nc2)c2F)c1)S(C)(=O)=O)=O ZHMNTLOSFHIVMF-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N CC(C)N1CCNCC1 Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- YACAUMLIXMVUBX-MRVPVSSYSA-N CC(C)N1C[C@@H](C)NCC1 Chemical compound CC(C)N1C[C@@H](C)NCC1 YACAUMLIXMVUBX-MRVPVSSYSA-N 0.000 description 1
- GGROKFCODOVWLX-QMMMGPOBSA-N CC(C)N1[C@@H](C)CNCC1 Chemical compound CC(C)N1[C@@H](C)CNCC1 GGROKFCODOVWLX-QMMMGPOBSA-N 0.000 description 1
- ZZMDOTWZZOLFDG-BDAKNGLRSA-N CC(C)N1[C@@H](C)CN[C@H](C)C1 Chemical compound CC(C)N1[C@@H](C)CN[C@H](C)C1 ZZMDOTWZZOLFDG-BDAKNGLRSA-N 0.000 description 1
- SJUHUWQFGXKELR-LBAQZLPGSA-N CC(C)c1cc(CCNc2nc(-c3cc(CN4[C@@H](C)CNC(C)C4)ccc3)ccn2)ccc1O Chemical compound CC(C)c1cc(CCNc2nc(-c3cc(CN4[C@@H](C)CNC(C)C4)ccc3)ccn2)ccc1O SJUHUWQFGXKELR-LBAQZLPGSA-N 0.000 description 1
- YNCZMAGHAVEQMU-IRCUZVAFSA-N CC1N(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C[C@H](C(N)=O)NC1 Chemical compound CC1N(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C[C@H](C(N)=O)NC1 YNCZMAGHAVEQMU-IRCUZVAFSA-N 0.000 description 1
- ZAPHFUVMIMFDSS-YQXBWWBASA-O CC1N(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C[C@H](C(NC(N(C)N)N=[NH2+])=O)NC1 Chemical compound CC1N(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C[C@H](C(NC(N(C)N)N=[NH2+])=O)NC1 ZAPHFUVMIMFDSS-YQXBWWBASA-O 0.000 description 1
- CLPZHEDSMNQBPP-UHFFFAOYSA-N CC1NC(C)CN(C)C1 Chemical compound CC1NC(C)CN(C)C1 CLPZHEDSMNQBPP-UHFFFAOYSA-N 0.000 description 1
- QYFIVLKGLMDKJX-UHFFFAOYSA-N CC1NCC(C)N(Cc2cccc(-c3ccnc(NCCC(CC4(C)OS(N)(=O)=O)=CC=C4O)n3)c2)C1 Chemical compound CC1NCC(C)N(Cc2cccc(-c3ccnc(NCCC(CC4(C)OS(N)(=O)=O)=CC=C4O)n3)c2)C1 QYFIVLKGLMDKJX-UHFFFAOYSA-N 0.000 description 1
- SUCFMTMQOQUHFV-UHFFFAOYSA-N CC1NCC(C)N(Cc2cccc(-c3ccnc(NCCc(cc4O)ccc4OS(N)(=O)=O)n3)c2)C1 Chemical compound CC1NCC(C)N(Cc2cccc(-c3ccnc(NCCc(cc4O)ccc4OS(N)(=O)=O)n3)c2)C1 SUCFMTMQOQUHFV-UHFFFAOYSA-N 0.000 description 1
- GWTSFWMDTLOQTC-UHFFFAOYSA-N CC1NCCN(C)C1C Chemical compound CC1NCCN(C)C1C GWTSFWMDTLOQTC-UHFFFAOYSA-N 0.000 description 1
- BDCVLJJYHJRCHA-VLXMWBNISA-N CC1NC[C@H](C)N(Cc2cccc(-c3[n+](CNCCC(C=C4C(C)(C)C)=CCC4(C)O)[n-]cc3)c2)C1 Chemical compound CC1NC[C@H](C)N(Cc2cccc(-c3[n+](CNCCC(C=C4C(C)(C)C)=CCC4(C)O)[n-]cc3)c2)C1 BDCVLJJYHJRCHA-VLXMWBNISA-N 0.000 description 1
- BPELVIHYKUICKV-UHFFFAOYSA-N CCC(CN(CC1)CC(C2=CC(F)=CC(CCNc3nc-4ccn3)C2C)=C)N1Cc1ccc(C)c-4c1 Chemical compound CCC(CN(CC1)CC(C2=CC(F)=CC(CCNc3nc-4ccn3)C2C)=C)N1Cc1ccc(C)c-4c1 BPELVIHYKUICKV-UHFFFAOYSA-N 0.000 description 1
- AESTZWCYHGSRMV-UHFFFAOYSA-N CCN(C1)C2C1(C1)C1NC2 Chemical compound CCN(C1)C2C1(C1)C1NC2 AESTZWCYHGSRMV-UHFFFAOYSA-N 0.000 description 1
- RTPCYHNQLCTIKB-UHFFFAOYSA-N CCN(C1CNCC1)S(C)(=O)=O Chemical compound CCN(C1CNCC1)S(C)(=O)=O RTPCYHNQLCTIKB-UHFFFAOYSA-N 0.000 description 1
- OUXRMEUJNPVXMM-UHFFFAOYSA-N CCN(CC)C1CCNCC1 Chemical compound CCN(CC)C1CCNCC1 OUXRMEUJNPVXMM-UHFFFAOYSA-N 0.000 description 1
- YLKHBURUABBJSJ-UHFFFAOYSA-N CCN(CC1NCCC1)Cc1cc(-c2ccnc(NCCc3cccc(F)c3)n2)ccc1 Chemical compound CCN(CC1NCCC1)Cc1cc(-c2ccnc(NCCc3cccc(F)c3)n2)ccc1 YLKHBURUABBJSJ-UHFFFAOYSA-N 0.000 description 1
- NKBOEIBOILWCHT-UHFFFAOYSA-N CCN(CCCN)Cc1cccc(-c(nc(NCCc(cc2F)ccc2O)nc2)c2F)c1 Chemical compound CCN(CCCN)Cc1cccc(-c(nc(NCCc(cc2F)ccc2O)nc2)c2F)c1 NKBOEIBOILWCHT-UHFFFAOYSA-N 0.000 description 1
- BZLZNVQQOYYSLB-UHFFFAOYSA-N CCN(CCCN)Cc1cccc(-c(nc(NCCc2cccc(Cl)c2)nc2)c2F)c1 Chemical compound CCN(CCCN)Cc1cccc(-c(nc(NCCc2cccc(Cl)c2)nc2)c2F)c1 BZLZNVQQOYYSLB-UHFFFAOYSA-N 0.000 description 1
- FHWMJZBZUZQWIU-UHFFFAOYSA-N CCN(CCCN)Cc1cccc(-c(nc(NCCc2cccc(F)c2)nc2)c2F)c1 Chemical compound CCN(CCCN)Cc1cccc(-c(nc(NCCc2cccc(F)c2)nc2)c2F)c1 FHWMJZBZUZQWIU-UHFFFAOYSA-N 0.000 description 1
- XMYKAEKIZQFNCQ-UHFFFAOYSA-N CCN(CCN1CCNCC1)Cc1cccc(-c2ccnc(NCCc3cc(F)cc(F)c3)n2)c1 Chemical compound CCN(CCN1CCNCC1)Cc1cccc(-c2ccnc(NCCc3cc(F)cc(F)c3)n2)c1 XMYKAEKIZQFNCQ-UHFFFAOYSA-N 0.000 description 1
- HXDOZKJGKXYMEW-UHFFFAOYSA-N CCc(cc1)ccc1O Chemical compound CCc(cc1)ccc1O HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 1
- ZONOPRWLKWIXSB-PMACEKPBSA-N CCc1cc(CCNc2nc(C3=CCCC(CN4[C@@H](C)CN[C@@H](C)C4)=C3)ccn2)ccc1O Chemical compound CCc1cc(CCNc2nc(C3=CCCC(CN4[C@@H](C)CN[C@@H](C)C4)=C3)ccn2)ccc1O ZONOPRWLKWIXSB-PMACEKPBSA-N 0.000 description 1
- LARDJFNYULCZTN-UHFFFAOYSA-N CN(CCNCC1)S1(=O)=O Chemical compound CN(CCNCC1)S1(=O)=O LARDJFNYULCZTN-UHFFFAOYSA-N 0.000 description 1
- NLPBHBOKAYFGMZ-UHFFFAOYSA-N COc1cc(CCNc(nc2)nc(-c3cccc(CN(C4CCNCC4)S(C)(=O)=O)c3)c2F)ccc1O Chemical compound COc1cc(CCNc(nc2)nc(-c3cccc(CN(C4CCNCC4)S(C)(=O)=O)c3)c2F)ccc1O NLPBHBOKAYFGMZ-UHFFFAOYSA-N 0.000 description 1
- RYDQRTQSQNAAEE-UHFFFAOYSA-N CS(N(Cc1cc(-c(nc(NCCc2cccc(Cl)c2)nc2)c2F)ccc1)C1CCNCC1)(=O)=O Chemical compound CS(N(Cc1cc(-c(nc(NCCc2cccc(Cl)c2)nc2)c2F)ccc1)C1CCNCC1)(=O)=O RYDQRTQSQNAAEE-UHFFFAOYSA-N 0.000 description 1
- VQTGFLYHOBRJNO-GAJHUEQPSA-N C[C@@H]1N(Cc2cccc(-c3ccnc(NCCc(cc4)ccc4O)n3)c2)C[C@H](C(F)(F)F)NC1 Chemical compound C[C@@H]1N(Cc2cccc(-c3ccnc(NCCc(cc4)ccc4O)n3)c2)C[C@H](C(F)(F)F)NC1 VQTGFLYHOBRJNO-GAJHUEQPSA-N 0.000 description 1
- PXLADLNRBNMWRP-XJDOXCRVSA-N C[C@@H]1NCC(C)N(Cc2cccc(-c3[n+](CNCCc(cc4)cc(S(C)(=O)=O)c4O)[n-]cc3)c2)C1 Chemical compound C[C@@H]1NCC(C)N(Cc2cccc(-c3[n+](CNCCc(cc4)cc(S(C)(=O)=O)c4O)[n-]cc3)c2)C1 PXLADLNRBNMWRP-XJDOXCRVSA-N 0.000 description 1
- GEAPQDTWWQGYLL-ACXWBZAVSA-N C[C@@H]1NCC(C)N(Cc2cccc(-c3ccnc(NCCc(cc4O)ccc4S(C)=O)n3)c2)C1 Chemical compound C[C@@H]1NCC(C)N(Cc2cccc(-c3ccnc(NCCc(cc4O)ccc4S(C)=O)n3)c2)C1 GEAPQDTWWQGYLL-ACXWBZAVSA-N 0.000 description 1
- HMLPFDAJKRCOAZ-WHFBIAKZSA-N C[C@@H]1NC[C@@H](C(NC(N)N)=O)NC1 Chemical compound C[C@@H]1NC[C@@H](C(NC(N)N)=O)NC1 HMLPFDAJKRCOAZ-WHFBIAKZSA-N 0.000 description 1
- CDHYSFKPWCVXHZ-BQBZGAKWSA-N C[C@@H]1NC[C@H](C)N(C)C1 Chemical compound C[C@@H]1NC[C@H](C)N(C)C1 CDHYSFKPWCVXHZ-BQBZGAKWSA-N 0.000 description 1
- RUBNQABFFIZGOD-OALUTQOASA-N C[C@@H]1NC[C@H](C)N(Cc2cc(-c3ccnc(NCCc(cc4O)ccc4S(C)(=O)=O)n3)ccc2)C1 Chemical compound C[C@@H]1NC[C@H](C)N(Cc2cc(-c3ccnc(NCCc(cc4O)ccc4S(C)(=O)=O)n3)ccc2)C1 RUBNQABFFIZGOD-OALUTQOASA-N 0.000 description 1
- UOYFOEVWRIQFIV-FILNNYQLSA-N C[C@@H]1NC[C@H](C)N(Cc2cccc(-c3[n+](CNCCc(cc4S(C)=O)ccc4O)[n-]cc3)c2)C1 Chemical compound C[C@@H]1NC[C@H](C)N(Cc2cccc(-c3[n+](CNCCc(cc4S(C)=O)ccc4O)[n-]cc3)c2)C1 UOYFOEVWRIQFIV-FILNNYQLSA-N 0.000 description 1
- DZASKAJJERLOKL-OCOBAGFRSA-N C[C@@H]1NC[C@H](C)N(Cc2cccc(-c3ccnc(NCCC(C=C4C(F)(F)F)=CCC4(C)O)n3)c2)C1 Chemical compound C[C@@H]1NC[C@H](C)N(Cc2cccc(-c3ccnc(NCCC(C=C4C(F)(F)F)=CCC4(C)O)n3)c2)C1 DZASKAJJERLOKL-OCOBAGFRSA-N 0.000 description 1
- XVQFDDRBUPZLIO-LIXIDFRTSA-N C[C@H](CNCC1)C1NCc1cccc(-c2ccnc(NCCc3cc(F)cc(F)c3)n2)c1 Chemical compound C[C@H](CNCC1)C1NCc1cccc(-c2ccnc(NCCc3cc(F)cc(F)c3)n2)c1 XVQFDDRBUPZLIO-LIXIDFRTSA-N 0.000 description 1
- BXJHXORKNSCVGR-UHFFFAOYSA-N OC(C1NCCN(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C1)=O Chemical compound OC(C1NCCN(Cc2cc(-c3ccnc(NCCc(cc4)ccc4O)n3)ccc2)C1)=O BXJHXORKNSCVGR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53489804P | 2004-01-08 | 2004-01-08 | |
| PCT/US2005/000663 WO2005066139A2 (en) | 2004-01-08 | 2005-01-10 | 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517895A true JP2007517895A (ja) | 2007-07-05 |
| JP2007517895A5 JP2007517895A5 (enExample) | 2008-01-24 |
Family
ID=34749013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549475A Pending JP2007517895A (ja) | 2004-01-08 | 2005-01-10 | 炎症疾患を処置するのに有用な2−(アミノ置換)−4−アリールピリミジンおよび関連化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7732444B2 (enExample) |
| EP (2) | EP2123647A1 (enExample) |
| JP (1) | JP2007517895A (enExample) |
| AR (1) | AR047185A1 (enExample) |
| AT (1) | ATE437861T1 (enExample) |
| AU (1) | AU2005204060A1 (enExample) |
| CA (1) | CA2559888A1 (enExample) |
| CY (1) | CY1109529T1 (enExample) |
| DE (1) | DE602005015677D1 (enExample) |
| DK (1) | DK1701944T3 (enExample) |
| ES (1) | ES2330863T3 (enExample) |
| HR (1) | HRP20090572T1 (enExample) |
| PL (1) | PL1701944T3 (enExample) |
| PT (1) | PT1701944E (enExample) |
| RS (1) | RS51091B (enExample) |
| SI (1) | SI1701944T1 (enExample) |
| TW (1) | TW200533357A (enExample) |
| WO (1) | WO2005066139A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| US20080318929A1 (en) * | 2005-12-21 | 2008-12-25 | Barbosa Antonio J M | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta |
| CA2644643C (en) * | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| DK2430921T3 (en) * | 2007-04-03 | 2017-10-16 | Du Pont | SUBSTITUTED BENZEN FUNGICIDES |
| MX2010004740A (es) | 2007-10-30 | 2010-05-27 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico. |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
| EP2169665B1 (en) | 2008-09-25 | 2018-05-02 | LG Electronics Inc. | A method and an apparatus for processing a signal |
| WO2011083483A2 (en) * | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| CA2800936A1 (en) * | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
| ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
| EP2739618B1 (en) | 2011-08-04 | 2015-09-16 | Array Biopharma, Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| AR090220A1 (es) | 2012-03-01 | 2014-10-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| SMT201800608T1 (it) | 2012-04-24 | 2019-01-11 | Vertex Pharma | Inibitori di dna-pk |
| MX369989B (es) | 2012-08-27 | 2019-11-27 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. |
| AU2014244555B2 (en) | 2013-03-12 | 2018-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| ES2851724T3 (es) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Modulación de células madre |
| HUE041877T2 (hu) | 2013-10-17 | 2019-06-28 | Vertex Pharma | (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként |
| US10485772B2 (en) | 2014-08-25 | 2019-11-26 | EpiAxis Therapeutics Pty Ltd. | Compositions for modulating cancer stem cells and uses therefor |
| US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| EP4444423A1 (en) | 2021-12-06 | 2024-10-16 | Helmholtz-Zentrum Dresden - Rossendorf e.V. | 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526230A (ja) * | 1997-12-19 | 2001-12-18 | スミスクライン・ビーチャム・コーポレイション | ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用 |
| WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2002083667A2 (en) * | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US20020156087A1 (en) * | 1998-06-19 | 2002-10-24 | Nuss John M. | Inhibitors of glycogen synthase kinase 3 |
| JP2003520197A (ja) * | 1999-05-14 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | サイトカイン阻害活性をもつ化合物 |
| JP2003531103A (ja) * | 1999-08-12 | 2003-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−JUNN−末端キナーゼ(JNK)および他のタンパク質キナーゼの阻害剤 |
| JP2006525266A (ja) * | 2003-05-02 | 2006-11-09 | ノバルティス アクチエンゲゼルシャフト | ホスファチジルイノシトール3−キナーゼの阻害剤 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698697A (en) | 1995-07-19 | 1997-12-16 | Mitsubishi Chemical Corporation | 2-cyanopiperazine and method of producing the same |
| KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
| ATE274510T1 (de) * | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
| EE200100341A (et) * | 1998-12-24 | 2002-12-16 | Aventis Pharmaceuticals Products Inc. | Asendatud (aminoiminometüül- või aminometüül)bensoheteroarüülühendid, nende kasutamine ja farmatseutiline kompositsioon |
| JP2003503354A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Srcキナーゼ阻害剤化合物 |
| GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| US6869956B2 (en) | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
| AU1152702A (en) | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| GB0112803D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| MXPA04004166A (es) * | 2001-11-07 | 2004-07-08 | Hoffmann La Roche | Aminopirimidinas y piridinas. |
| TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| CA2489458A1 (en) * | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
| TW200510311A (en) | 2002-12-23 | 2005-03-16 | Millennium Pharm Inc | CCr8 inhibitors |
| EP1590334B1 (en) * | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| AU2004229392A1 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| US7459460B2 (en) * | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| ES2505090T3 (es) * | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
| BRPI0511978A (pt) * | 2004-06-10 | 2008-01-22 | Irm Llc | compostos e composições como inibidores de proteìnas quinases |
| JP2008519034A (ja) * | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
| TWI359810B (en) | 2004-11-04 | 2012-03-11 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivative containing thiazole rin |
| MX2007007032A (es) * | 2004-12-17 | 2007-07-04 | Amgen Inc | Compuestos de aminopirimidina y metodos de uso. |
| US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| DE102005034821A1 (de) * | 2005-07-26 | 2007-02-08 | Fleissner Gmbh | Voluminöse Faserlaminate und ihre Herstellung |
| TWM293131U (en) * | 2006-01-10 | 2006-07-01 | Shuen Tai Prec Entpr Co Ltd | Handheld power hammer |
-
2005
- 2005-01-07 TW TW094100533A patent/TW200533357A/zh unknown
- 2005-01-10 DK DK05726205T patent/DK1701944T3/da active
- 2005-01-10 PT PT05726205T patent/PT1701944E/pt unknown
- 2005-01-10 ES ES05726205T patent/ES2330863T3/es not_active Expired - Lifetime
- 2005-01-10 SI SI200530816T patent/SI1701944T1/sl unknown
- 2005-01-10 AT AT05726205T patent/ATE437861T1/de active
- 2005-01-10 RS RSP-2009/0466A patent/RS51091B/sr unknown
- 2005-01-10 PL PL05726205T patent/PL1701944T3/pl unknown
- 2005-01-10 HR HR20090572T patent/HRP20090572T1/hr unknown
- 2005-01-10 EP EP09009692A patent/EP2123647A1/en not_active Withdrawn
- 2005-01-10 EP EP05726205A patent/EP1701944B1/en not_active Expired - Lifetime
- 2005-01-10 CA CA002559888A patent/CA2559888A1/en not_active Abandoned
- 2005-01-10 JP JP2006549475A patent/JP2007517895A/ja active Pending
- 2005-01-10 US US11/032,299 patent/US7732444B2/en not_active Expired - Fee Related
- 2005-01-10 DE DE602005015677T patent/DE602005015677D1/de not_active Expired - Lifetime
- 2005-01-10 WO PCT/US2005/000663 patent/WO2005066139A2/en not_active Ceased
- 2005-01-10 AR ARP050100080A patent/AR047185A1/es unknown
- 2005-01-10 AU AU2005204060A patent/AU2005204060A1/en not_active Abandoned
-
2009
- 2009-10-27 CY CY20091101118T patent/CY1109529T1/el unknown
-
2010
- 2010-04-26 US US12/767,139 patent/US8268822B2/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526230A (ja) * | 1997-12-19 | 2001-12-18 | スミスクライン・ビーチャム・コーポレイション | ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用 |
| US20020156087A1 (en) * | 1998-06-19 | 2002-10-24 | Nuss John M. | Inhibitors of glycogen synthase kinase 3 |
| JP2003520197A (ja) * | 1999-05-14 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | サイトカイン阻害活性をもつ化合物 |
| JP2003531103A (ja) * | 1999-08-12 | 2003-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−JUNN−末端キナーゼ(JNK)および他のタンパク質キナーゼの阻害剤 |
| WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2002083667A2 (en) * | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| JP2006525266A (ja) * | 2003-05-02 | 2006-11-09 | ノバルティス アクチエンゲゼルシャフト | ホスファチジルイノシトール3−キナーゼの阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8268822B2 (en) | 2012-09-18 |
| AR047185A1 (es) | 2006-01-11 |
| WO2005066139A2 (en) | 2005-07-21 |
| DE602005015677D1 (de) | 2009-09-10 |
| EP1701944A2 (en) | 2006-09-20 |
| US20060040968A1 (en) | 2006-02-23 |
| US7732444B2 (en) | 2010-06-08 |
| PT1701944E (pt) | 2009-11-03 |
| ES2330863T3 (es) | 2009-12-16 |
| EP2123647A1 (en) | 2009-11-25 |
| ATE437861T1 (de) | 2009-08-15 |
| WO2005066139A3 (en) | 2005-10-13 |
| SI1701944T1 (sl) | 2010-03-31 |
| PL1701944T3 (pl) | 2010-01-29 |
| CY1109529T1 (el) | 2014-08-13 |
| US20110071134A1 (en) | 2011-03-24 |
| TW200533357A (en) | 2005-10-16 |
| RS51091B (sr) | 2010-10-31 |
| HRP20090572T1 (hr) | 2010-01-31 |
| AU2005204060A1 (en) | 2005-07-21 |
| EP1701944B1 (en) | 2009-07-29 |
| DK1701944T3 (da) | 2009-11-09 |
| CA2559888A1 (en) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8268822B2 (en) | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | |
| AU2002220195B2 (en) | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | |
| EP1442024B1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | |
| US20100113445A1 (en) | Chemical Compounds | |
| US20190337940A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CN112533904B (zh) | 黑皮质素亚型-2受体(mc2r)拮抗剂及其用途 | |
| JP6635949B2 (ja) | 炎症性および自己免疫性の病気の処置のためのmth1阻害剤 | |
| US20170217961A1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| TW201024307A (en) | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | |
| JP2022521901A (ja) | タンパク質キナーゼ阻害活性を有する新規なピリド[3,4-d]ピリミジン-8-オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 | |
| EA011809B1 (ru) | Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения | |
| RS55793B1 (sr) | 6-alkinil piridini kao smac mimetici | |
| HUE035919T2 (en) | Macrocyclic pyridazinone derivatives | |
| JP2010523637A (ja) | 医薬化合物 | |
| TW201336825A (zh) | 雙環芳基及雜芳基化合物之鈉通道抑制劑 | |
| CN105859689A (zh) | 作为mTOR和PI3K抑制剂的新颖嘧啶化合物 | |
| JP2008505910A (ja) | Pkc−シータのインヒビターとして有用なピリミジン誘導体 | |
| AU2006335967B2 (en) | Novel heterocycles | |
| WO2024145505A1 (en) | Pyrimidine carboxamide compounds | |
| JP2010540423A (ja) | ピロロピリミジン化合物類 | |
| TWI525088B (zh) | 新穎之苯基吡啶衍生物及含有該衍生物之醫藥 | |
| HK1138280A (en) | 2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases | |
| RU2795572C2 (ru) | Соединения и композиции для ингибирования ire1 | |
| WO2024167927A1 (en) | Compounds, compositions and methods of use thereof | |
| JP2024528729A (ja) | Srpkインヒビター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101220 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110711 |